DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

PEG-Intron (Peginterferon Alfa-2B) - Tremor - Suspected Cause - Side Effect Reports

 
 



Index of reports > Cases with Tremor ()

Below is the selection of side effect reports (a.k.a. adverse event reports) related to PEG-Intron (Peginterferon Alfa-2B) where reactions include tremor. The selected reports were submitted to the FDA during the sample period of about a year.

Possible PEG-Intron side effects in

Reported by a physician from United States on 2012-08-23

Patient:

Reactions: Fatigue, Alopecia, Vision Blurred, Depression, Rash, Tremor

Drug(s) suspected as cause:
PEG-Intron



Possible PEG-Intron side effects in

Reported by a physician from United States on 2012-08-23

Patient:

Reactions: Contusion, Head Discomfort, Somnolence, Fall, Abdominal Pain Upper, Loss of Consciousness, Fatigue, Dizziness, Blood Creatinine Increased, Migraine, Back Pain, Nausea, Hypotension, Convulsion, Eye Pain, Tremor

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-05-09

Rebetol
    Dosage: unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-05-09

Victrelis
    Dosage: unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-07



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-10

Patient:

Reactions: Pain, Polyuria, Headache, Pyrexia, Myalgia, Mood Altered, Neck Pain, Chest Pain, DRY Mouth, Breath Odour, Dizziness, Depression, Sinus Congestion, Nausea, Anaemia, Glucose Tolerance Impaired, Hypoaesthesia, Oropharyngeal Discomfort, Tremor, Mental Impairment, Sleep Disorder, Visual Impairment, Asthenia, Feeling Abnormal

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 150 microgram, qw
    Indication: Hepatitis C
    Start date: 2012-03-09

Rebetol
    Dosage: 200 mg, unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-03-09

Telaprevir
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-03-09

Other drugs received by patient: Valium; Advil; Xanax; Ambien



Possible PEG-Intron side effects in

Reported by a consumer/non-health professional from United States on 2012-08-10

Patient:

Reactions: Tremor

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-06-22
    End date: 2012-07-13

Rebetol
    Dosage: unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-06-22
    End date: 2012-07-13



Possible PEG-Intron side effects in

Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-04

Patient:

Reactions: Back Pain, Contusion, Head Discomfort, Nausea, Hypotension, Fall, Eye Pain, Loss of Consciousness, Convulsion, Tremor, Abdominal Pain Upper, Fatigue, Dizziness, Blood Creatinine Increased

Drug(s) suspected as cause:
PEG-Intron
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-05-09

Rebetol
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-05-09

Victrelis
    Dosage: unk
    Indication: Hepatitis C
    Start date: 2012-06-07



Possible PEG-Intron side effects in

Reported by a physician from Japan on 2012-07-05

Patient:

Reactions: Collagen Disorder, Blood Uric Acid Increased, Haemorrhoids, Disseminated Intravascular Coagulation, Erythema Multiforme, Tremor

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.3 mcg/kg, qw, sc
    Indication: Hepatitis C
    Start date: 2011-12-21
    End date: 2012-03-07

Rebetol
    Dosage: 400 mg, qd, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-12-21
    End date: 2012-03-14

Telavic (Antivirals Nos)
    Dosage: 1500 mg, qd, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-12-21
    End date: 2012-03-13

Other drugs received by patient: Loxonin; Zoloft; Maglax; Meilax; Primperan TAB; Betamethasone Sodium Phosphate; Nitrazepam; Voltaren; Selbrex



Possible PEG-Intron side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-02

Patient: female

Reactions: Drug Dose Omission, Confusional State, Vomiting, Nausea, Drug Withdrawal Syndrome, Tremor, Diarrhoea, Neck Pain, Presyncope, Cold Sweat

Drug(s) suspected as cause:
Morphine
    Indication: Product Used FOR Unknown Indication

PEG-Intron
    Indication: Hepatitis C
    Start date: 2012-03-18

Ribavirin
    Indication: Hepatitis C
    Start date: 2012-03-18

Victrelis
    Indication: Hepatitis C
    Start date: 2012-04-15



Possible PEG-Intron side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-06-08

Patient: female

Reactions: Weight Decreased, Pneumonia, Hepatitis C, Abasia, Fall, Tremor, Concussion, Disease Recurrence, Facial Bones Fracture

Drug(s) suspected as cause:
PEG-Intron
    Indication: Hepatitis C
    Start date: 2003-01-01
    End date: 2003-07-01

PEG-Intron
    Indication: Hepatitis C
    Start date: 2012-02-14

Ribavirin
    Indication: Hepatitis C
    Start date: 2012-02-14

Ribavirin
    Indication: Hepatitis C
    Start date: 2003-01-01
    End date: 2003-07-01



Possible PEG-Intron side effects in 56 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-24

Patient: 56 year old female

Reactions: Weight Decreased, Nausea, Faecal Incontinence, Headache, Fall, Hyperhidrosis, Tremor, Injection Site Erythema, Diarrhoea, RED Blood Cell Count Decreased, Balance Disorder, Hypophagia, Alopecia, Injection Site Rash, Hallucination

Drug(s) suspected as cause:
PEG-Intron
    Indication: Hepatitis C
    Start date: 2011-06-16

Ribavirin
    Indication: Hepatitis C
    Start date: 2011-06-16

Victrelis
    Indication: Hepatitis C
    Start date: 2011-07-28
    End date: 2011-08-05



Possible PEG-Intron side effects in 5 year old male

Reported by a health professional (non-physician/pharmacist) from United States on 2012-05-09

Patient: 5 year old male, weighing 32.5 kg (71.5 pounds)

Reactions: Renal Tubular Disorder, Dyskinesia, Disseminated Intravascular Coagulation, Petechiae, Hepatic Failure, Mental Status Changes, Coma, Headache, Pyrexia, Lactic Acidosis, Urine Output Increased, Generalised Oedema, Malaise, Acute Respiratory Distress Syndrome, Pulmonary Oedema, Electrolyte Imbalance, Vomiting, International Normalised Ratio Increased, Respiratory Distress, Tremor, Nephrogenic Diabetes Insipidus, Convulsion, Renal Failure, Product Packaging Issue, Mitochondrial Toxicity, Depressed Level of Consciousness, Rash Maculo-Papular, Multi-Organ Disorder, Shock

Adverse event resulted in: life threatening event, hospitalization

Drug(s) suspected as cause:
Acetaminophen
    Dosage: 445 mg;once;rtl
    Indication: Product Used FOR Unknown Indication
    Start date: 2010-01-07

Acetaminophen
    Dosage: 400 mg;once ; 400 mg;once
    Indication: Product Used FOR Unknown Indication
    Start date: 2010-01-07

Acetaminophen
    Dosage: 400 mg;once ; 400 mg;once
    Indication: Product Used FOR Unknown Indication
    Start date: 2010-01-07

PEG-Intron
    Dosage: 64 mcg;sc
    Indication: Hepatitis C
    Start date: 2010-01-07
    End date: 2010-01-07

Rebetol
    Dosage: 240 mg;po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2010-01-07
    End date: 2010-01-07



Possible PEG-Intron side effects in 53 year old female

Reported by a physician from Japan on 2012-04-13

Patient: 53 year old female, weighing 64.0 kg (140.8 pounds)

Reactions: Nausea, Haemorrhoids, Disseminated Intravascular Coagulation, Rash Papular, Tremor, Collagen Disorder, Blood Uric Acid Increased, Injection Site Reaction, Erythema Multiforme, Papule

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 1.3 mcg/kg;qw;sc
    Indication: Hepatitis C
    Start date: 2011-12-21

Rebetol
    Dosage: 400 mg;qd;po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-12-21

Telavic (Antivirals Nos)
    Dosage: 1500 mg;qd;po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-12-21
    End date: 2012-03-13

Other drugs received by patient: Voltaren / 01160501 /; Primperan / 00041902 /; Magnesium Sulfate; Loxonin / 00890701 /; Selbex; Zoloft; Rinderon-VG; Meilax; Nitrazepam



Possible PEG-Intron side effects in 57 year old female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-02-15

Patient: 57 year old female, weighing 70.4 kg (154.9 pounds)

Reactions: Vomiting, Nausea, Dehydration, Asthenia, Tremor, Walking AID User

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded MK-5172
    Dosage: 8; 3 df
    Indication: Hepatitis C
    Start date: 2011-10-07
    End date: 2011-10-19

Blinded MK-5172
    Dosage: 8; 3 df
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Blinded MK-5172
    Dosage: 8; 3 df
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Blinded MK-5172
    Dosage: 8; 3 df
    Indication: Hepatitis C
    Start date: 2011-09-21
    End date: 2011-10-19

Blinded MK-5172
    Dosage: 8; 3 df
    Indication: Hepatitis C
    Start date: 2011-09-21
    End date: 2011-09-21

Blinded MK-5172
    Dosage: 8; 3 df
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-09-20

Blinded MK-5172
    Dosage: 8; 3 df
    Indication: Hepatitis C
    Start date: 2011-10-06
    End date: 2011-10-06

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-11-14
    End date: 2011-11-14

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-11-21
    End date: 2011-11-21

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-11-29
    End date: 2011-11-29

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2012-01-02
    End date: 2012-01-02

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-09-20

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-12-12
    End date: 2011-12-12

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-11-07
    End date: 2011-11-07

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-31
    End date: 2011-10-31

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-10
    End date: 2011-10-10

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-12-05
    End date: 2011-12-05

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2012-01-08
    End date: 2012-01-08

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-09-26
    End date: 2011-09-26

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-03
    End date: 2011-10-03

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-17
    End date: 2011-10-17

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-12-19
    End date: 2011-12-19

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-24
    End date: 2011-10-24

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-12-26
    End date: 2011-12-26

Placebo
    Dosage: 12 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Placebo
    Dosage: 12 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-23
    End date: 2011-11-28

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-24
    End date: 2011-11-28

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-06
    End date: 2011-10-06

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-07
    End date: 2011-11-16

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-12-15
    End date: 2011-12-19

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-10-19

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-22

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-12-20
    End date: 2012-01-03

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-21
    End date: 2011-10-05

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-12-15
    End date: 2012-01-11

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2012-01-04
    End date: 2012-01-10

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-29
    End date: 2011-12-14

Other drugs received by patient: Deplin; Lysine; Effexor; Ibuprofen; Effexor; Loratadine; Wellbutrin; Vitamin B Complex CAP; Valtrex; Wellbutrin; Omeprazole; Zofran; Wellbutrin; Ibuprofen



Possible PEG-Intron side effects in 57 year old female

Reported by a physician from United States on 2012-02-09

Patient: 57 year old female, weighing 70.4 kg (154.9 pounds)

Reactions: Vomiting, Dehydration, Asthenia, Tremor

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded MK-5172
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Blinded MK-5172
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-10-06
    End date: 2011-10-07

Blinded MK-5172
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-09-20

Blinded MK-5172
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-09-21
    End date: 2011-10-19

Blinded MK-5172
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Blinded MK-5172
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-09-21
    End date: 2011-09-22

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-11-14
    End date: 2011-11-14

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-11-21
    End date: 2011-11-21

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-10-03
    End date: 2011-10-03

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-10-24
    End date: 2011-10-24

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-12-26
    End date: 2011-12-26

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-11-07
    End date: 2011-11-07

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-12-12
    End date: 2011-12-12

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-09-26
    End date: 2011-09-26

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-12-05
    End date: 2011-12-05

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-09-20

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-10-10
    End date: 2011-10-10

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-10-31
    End date: 2011-10-31

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-12-19
    End date: 2011-12-19

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2012-01-02
    End date: 2012-01-02

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-10-17
    End date: 2011-10-17

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-11-29
    End date: 2011-11-29

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2012-01-08
    End date: 2012-01-08

Placebo
    Dosage: df;tid;po df;unk; unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Placebo
    Dosage: df;tid;po df;unk; unk
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-09-21
    End date: 2011-10-05

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-11-29
    End date: 2011-12-14

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-11-29
    End date: 2011-12-14

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-12-15
    End date: 2012-01-11

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-12-20
    End date: 2012-01-03

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-10-19

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-22

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-10-07
    End date: 2011-11-16

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-11-24
    End date: 2011-11-28

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2012-01-04
    End date: 2012-01-10

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-11-23
    End date: 2011-11-28

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-12-15
    End date: 2011-12-19

Rebetol
    Dosage: see image
    Indication: Hepatitis C
    Start date: 2011-10-06
    End date: 2011-10-07

Other drugs received by patient: Loratadine; Lysine; Wellbutrin; Valtrex; Ibuprofen; Effexor; Deplin; Vitamin B Complex CAP; Omeprazole



Possible PEG-Intron side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2012-01-19

Patient: female

Reactions: Vomiting, Pleuritic Pain, Pleurisy, Anaemia, Hypotension, Pyrexia, Tremor, Dehydration, Asthenia

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
PEG-Intron
    Indication: Hepatitis C
    Start date: 2011-10-30

Ribavirin
    Indication: Hepatitis C
    Start date: 2011-10-30

Victrelis
    Indication: Hepatitis C
    Start date: 2011-11-27



Possible PEG-Intron side effects in 57 year old female

Reported by a physician from United States on 2012-01-03

Patient: 57 year old female, weighing 70.4 kg (154.9 pounds)

Reactions: Vomiting, Dehydration, Asthenia, Tremor

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded MK-5172
    Dosage: 8 df
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-10-19

Blinded MK-5172
    Dosage: 8 df
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Blinded MK-5172
    Dosage: 8 df
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Blinded MK-5172
    Dosage: 8 df
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-09-20

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-09-26
    End date: 2011-09-26

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-24
    End date: 2011-10-24

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-11-14
    End date: 2011-11-14

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-10
    End date: 2011-10-10

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-31
    End date: 2011-10-31

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-09-20

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-17
    End date: 2011-10-17

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-03
    End date: 2011-10-03

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-11-07
    End date: 2011-11-07

Placebo
    Dosage: 12 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Placebo
    Dosage: 12 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-10-19

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-24

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-29

Other drugs received by patient: Ibuprofen; Ibuprofen; Wellbutrin XL; Omeprazole; Wellbutrin; Effexor; Lysine; Vitamin B Complex CAP; Loratadine; Deplin; Valtrex



Possible PEG-Intron side effects in 57 year old female

Reported by a physician from United States on 2012-01-03

Patient: 57 year old female, weighing 70.4 kg (154.9 pounds)

Reactions: Vomiting, Nausea, Dehydration, Asthenia, Tremor

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded MK-5172
    Dosage: 8 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-09-20

Blinded MK-5172
    Dosage: 8 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Blinded MK-5172
    Dosage: 8 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Blinded MK-5172
    Dosage: 8 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-10-19

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-09-26
    End date: 2011-09-26

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-09-20

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-03
    End date: 2011-10-03

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-10
    End date: 2011-10-10

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-11-14
    End date: 2011-11-14

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-17
    End date: 2011-10-17

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-31
    End date: 2011-10-31

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-24
    End date: 2011-10-24

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-11-07
    End date: 2011-11-07

Placebo
    Dosage: 12 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Placebo
    Dosage: 12 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-10-19

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-29

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-24

Other drugs received by patient: Vitamin B Complex CAP; Lysine; Wellbutrin XL; Loratadine; Ibuprofen; Effexor; Valtrex; Deplin; Omeprazole; Wellbutrin; Ibuprofen



Possible PEG-Intron side effects in 57 year old female

Reported by a physician from United States on 2012-01-03

Patient: 57 year old female, weighing 70.4 kg (154.9 pounds)

Reactions: Vomiting, Nausea, Dehydration, Asthenia, Tremor

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded MK-5172
    Dosage: 8 df
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-11-16

Blinded MK-5172
    Dosage: 8 df
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-10-19

Blinded MK-5172
    Dosage: 8 df
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Blinded MK-5172
    Dosage: 8 df
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-09-26
    End date: 2011-09-26

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-03
    End date: 2011-10-03

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-24
    End date: 2011-10-24

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-17
    End date: 2011-10-17

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-09-20

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-31
    End date: 2011-10-31

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-10-10
    End date: 2011-10-10

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-11-14
    End date: 2011-11-14

PEG-Intron
    Dosage: 0.4 ml, qw, sc
    Indication: Hepatitis C
    Start date: 2011-11-07
    End date: 2011-11-07

Placebo
    Dosage: 12 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Placebo
    Dosage: 12 df, tid, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-10-19

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-17
    End date: 2011-11-23

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-29

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-20
    End date: 2011-10-19

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20
    End date: 2011-11-16

Rebetol
    Dosage: 2;3 df, qam, po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-11-24

Other drugs received by patient: Omeprazole; Deplin; Lysine; Wellbutrin; Wellbutrin; Omeprazole; Loratadine; Effexor; Valtrex; Vitamin B Complex CAP; Ibuprofen



Possible PEG-Intron side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2011-12-28

Patient: female

Reactions: Dyspnoea, Somnolence, Tremor, Blood Glucose Abnormal, Insomnia, Abdominal Distension, Thyroid Disorder, Platelet Count Decreased, Asthenia, Muscle Spasms

Drug(s) suspected as cause:
PEG-Intron
    Indication: Hepatitis C
    Start date: 2011-11-14

Ribavirin
    Indication: Hepatitis C
    Start date: 2011-11-14

Victrelis
    Indication: Hepatitis C
    Start date: 2011-12-12



Possible PEG-Intron side effects in female

Reported by a health professional (non-physician/pharmacist) from United States on 2011-12-23

Patient: female

Reactions: White Blood Cell Count Decreased, Gait Disturbance, Coordination Abnormal, Asthenia, Decreased Appetite, Tremor

Drug(s) suspected as cause:
PEG-Intron
    Dosage: 95 mcg qw sq
    Indication: Hepatitis C
    Start date: 2011-10-27

Ribasphere
    Dosage: 1000 mcg daily po
    Administration route: Oral
    Start date: 2011-10-27



Possible PEG-Intron side effects in 57 year old female

Reported by a physician from United States on 2011-12-19

Patient: 57 year old female, weighing 70.4 kg (154.9 pounds)

Reactions: Vomiting, Dehydration, Asthenia, Tremor

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded MK-5172
    Indication: Hepatitis C

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-09-20

Peginterferon Alfa-2B
    Dosage: 4 df;tid;po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20

Rebetol
    Dosage: 2 df;qam;po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-20

Other drugs received by patient: Deplin; Valtrex; Ibuprofen; Wellbutrin; Lysine; Effexor; Loratadine; Vitamin B Complex CAP



Possible PEG-Intron side effects in 57 year old female

Reported by a physician from United States on 2011-12-19

Patient: 57 year old female, weighing 70.4 kg (154.9 pounds)

Reactions: Vomiting, Nausea, Dehydration, Asthenia, Tremor

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Blinded MK-5172
    Indication: Hepatitis C

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-09-20

Peginterferon Alfa-2B
    Dosage: 4 df;tid;po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20

Rebetol
    Dosage: 2 df;qam;po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-20

Other drugs received by patient: Effexor; Valtrex; Deplin; Loratadine; Vitamin B Complex CAP; Lysine; Wellbutrin; Ibuprofen



Possible PEG-Intron side effects in 57 year old female

Reported by a physician from United States on 2011-12-14

Patient: 57 year old female, weighing 70.4 kg (154.9 pounds)

Reactions: Vomiting, Dehydration, Asthenia, Tremor

Adverse event resulted in: hospitalization

Drug(s) suspected as cause:
Boceprevir
    Dosage: 4 df;tid;po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-10-20

PEG-Intron
    Dosage: 0.4 ml;qw;sc
    Indication: Hepatitis C
    Start date: 2011-09-20

Rebetol
    Dosage: 2 df;qam;po
    Administration route: Oral
    Indication: Hepatitis C
    Start date: 2011-09-20

Other drugs received by patient: Effexor; Loratadine; Ibuprofen; Valtrex; Wellbutrin; Vitamin B Complex CAP; Deplin; Lysine

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014